Summary CB-13, also known as CRA13 and SAB-378, is a cannabinoid pharmaceutical compound. This substance is a robust agonist for CB1 and CB2 receptors, yet it cannot breach the blood-brain barrier. Consequently, at lower doses, CB-13 primarily elicits peripheral effects, while indications of central effects, such as catalepsy, manifest only when administered at significantly higher …
Summary BIM-018 is a synthetic cannabinoid belonging to the benzimidazole family and is considered the analog of JWH-018. It is believed to act as a potent agonist of the CB2 receptor and has been marketed online as a designer drug.Other benzimidazole derivatives with a similar structure have demonstrated high selectivity as agonists for the CB2 …
Sumamry Initially synthesized by chemist Wayne E. Kenney, BAY 38-7271 (also known as KN 38-7271) is a pharmaceutical compound developed by Bayer AG. This drug is a cannabinoid receptor agonist, exhibiting analgesic and neuroprotective properties. BAY 38-7271 is primarily employed in scientific research and has shown promise for potential applications in treating traumatic brain injury.In …
Summary AB-CHFUPYCA, also known as AB-CHMFUPPYCA, is a compound initially discovered as part of synthetic cannabis products in Japan back in 2015. The name “AB-CHFUPYCA” is an abbreviation derived from its systematic name, N-(1-Amino-3-methyl-1-oxoButan-2-yl)-1-(cyclohexylmethyl)-3-(4-FlUorophenyl)-1H-PYrazole-5-CarboxAmide. Two distinct regioisomers of AB-CHFUPYCA exist: 3,5-AB-CHMFUPPYCA and 5,3-AB-CHMFUPPYCA. Both collectively refer to as AB-CHMFUPPYCA isomers, meaning that AB-CHMFUPPYCA and AB-CHFUPYCA …
Summary A-836,339, a product of Abbott Laboratories, is a potent full agonist of the cannabinoid receptor. Notably, it exhibits selectivity for CB2, with Ki values of 0.64 nM at CB2 compared to 270 nM at the psychoactive CB1 receptor. At lower doses, A-836,339 displays selective analgesic, anti-inflammatory, and anti-hyperalgesic effects. However, its high efficacy at …
Summary 5F-PCN, also identified as 5F-MN-21, belongs to the category of azaindole-based synthetic cannabinoids. It is presumed to possess potent agonistic effects on the CB1 receptor and has found its way into online markets as a designer drug. Notably, it shares a close chemical relationship with NNE1.An intriguing aspect to consider is the metabolic processes …
summary 5F-AB-FUPPYCA, or AZ-037, is a synthetic cannabinoid rooted in the pyrazole structure. It is presumed to act as an agonist targeting the CB1 receptor and has gained popularity as a designer drug available for purchase online. Notably, it came into the spotlight when the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) identified …
Summary 3-(4-Hydroxymethylbenzoyl)-1-pentylindole is classified as a synthetic cannabinoid, and there are plans to include it in Schedule I-N in Poland. This compound was first reported to the EMCDDA and Europol in 2010 by the provisions of the European Council Decision 2005/387/JHA dated 10 May 2005, which pertains to the exchange of information, risk assessment, and …
Summary Clonidine, marketed under various trade names such as Catapres, Kapvay, Nexiclon, Clophelin, and more, is categorized as a depressant belonging to the imidazoline class of substances. While its primary application is in managing high blood pressure, it is versatile and can be employed for various medical conditions. These include attention deficit hyperactivity disorder, anxiety …
The market situation for MDA (3,4-methylenedioxyamphetamine) is undergoing significant changes, primarily influenced by shifting regulations and consumer preferences. MDA, once a prominent designer drug and research chemical, is now subject to increased scrutiny and restrictions.For sellers and vendors, the landscape has become increasingly challenging. Many online platforms have yet to crack down on the sale …
